Ginkgo Bioworks Holdings (DNA) EPS (Weighted Average and Diluted) (2020 - 2025)
Ginkgo Bioworks Holdings posted quarterly EPS (Weighted Average and Diluted) of -$1.42 for Q4 2025, up 27.55% year-on-year from -$1.11 in Q4 2024, and up 2.07% on a QoQ basis from -$1.45 in Q3 2025.
Ginkgo Bioworks Holdings (DNA) has 6 years of EPS (Weighted Average and Diluted) data on file, last reported at -$1.42 in Q4 2025.
- For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 27.55% year-over-year to -$1.42; the trailing twelve-month figure through Dec 2025 stood at -$5.65 (up 46.65% YoY), and the FY2025 full-year result was -$5.64, up 46.49% from the prior year.
- EPS (Weighted Average and Diluted) for Q4 2025 stood at -$1.42, up from -$1.45 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at -$0.04 in Q2 2021 and bottomed at -$49.01 in Q4 2022.
- The 5-year median for EPS (Weighted Average and Diluted) is -$1.21 (2021), against an average of -$4.13.
- The widest annual swing landed in 2023, when EPS (Weighted Average and Diluted) soared 91.27%; it then tumbled 4600.0% in 2024.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.21 in 2021, then tumbled by 3950.41% to -$49.01 in 2022, then jumped by 91.27% to -$4.28 in 2023, then soared by 54.21% to -$1.96 in 2024, then climbed by 27.55% to -$1.42 in 2025.
- The last three EPS (Weighted Average and Diluted) figures came in at -$1.42 (Q4 2025), -$1.45 (Q3 2025), and -$1.1 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Ginkgo Bioworks Holdings | 542.03 Mn | 542.03 Mn | 16.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.42 |
| Sep 30, 2025 | -1.45 |
| Jun 30, 2025 | -1.10 |
| Mar 31, 2025 | -1.68 |
| Dec 31, 2024 | -1.96 |
| Sep 30, 2024 | -1.08 |
| Jun 30, 2024 | -4.23 |
| Mar 31, 2024 | -3.32 |
| Dec 31, 2023 | -4.28 |
| Sep 30, 2023 | -6.21 |
| Jun 30, 2023 | -0.09 |
| Mar 31, 2023 | -0.11 |
| Dec 31, 2022 | -49.01 |
| Sep 30, 2022 | -0.41 |
| Jun 30, 2022 | -0.41 |
| Mar 31, 2022 | -0.37 |
| Dec 31, 2021 | -1.21 |
| Sep 30, 2021 | -0.08 |
| Jun 30, 2021 | -0.04 |
| Dec 31, 2020 | -0.04 |